Sagittarius Life Science Cash Flow-to-Debt Ratio
Sagittarius Life Science cash flow-to-debt ratio. Sagittarius Life Science (3205) has a Cash Flow-to-Debt Ratio of -0.79x as of December 2025, meaning its operating cash flow of NT$-21.27 Million could theoretically repay -1% of its total liabilities (NT$26.91 Million) in one year. Check cash flow quality index of Sagittarius Life Science to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Sagittarius Life Science (2015–2025)
Cash flow-to-debt ratio of Sagittarius Life Science from 2015 to 2025. Historical debt coverage capacity for Sagittarius Life Science across 11 annual periods. Check total reinvestment intensity of Sagittarius Life Science to assess the company's total reinvestment commitment from operating cash flow.
Sagittarius Life Science Cash Flow-to-Debt Ratio by Year (2015–2025)
Sagittarius Life Science cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Sagittarius Life Science. For the full cash flow conversion analysis, see 3205 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.34x | NT$-36.05 Million | NT$26.91 Million | ▼ -201.4% |
| 2024 | -0.44x | NT$-44.48 Million | NT$100.07 Million | ▲ +11.7% |
| 2023 | -0.50x | NT$-69.37 Million | NT$137.82 Million | ▼ -17.7% |
| 2022 | -0.43x | NT$-52.89 Million | NT$123.70 Million | ▼ -111.0% |
| 2021 | -0.20x | NT$-29.18 Million | NT$144.03 Million | ▲ +50.4% |
| 2020 | -0.41x | NT$-62.24 Million | NT$152.36 Million | ▲ +46.4% |
| 2019 | -0.76x | NT$-104.50 Million | NT$137.09 Million | ▼ -27.0% |
| 2018 | -0.60x | NT$-57.86 Million | NT$96.38 Million | ▼ -150.2% |
| 2017 | -0.24x | NT$-23.31 Million | NT$97.16 Million | ▼ -113.4% |
| 2016 | 1.80x | NT$360.37 Million | NT$200.51 Million | ▲ +215.0% |
| 2015 | 0.57x | NT$237.94 Million | NT$416.95 Million | — |